Developing A Vaccine To Protect Against Hypervirulent Strains Of Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$536,850.00
Summary
Epidemic invasive GAS disease is associated with the emergence of the globally disseminated M1T1 clone and is linked to the mutation in the CovR/S regulator. This mutation leads to over- expression of SpyCEP and inhibits recruitment of neutrophils to the site of infection. Inclusion of an immunogenic fragment of SpyCEP into our current vaccine would enhance its efficacy and lead to the development of a vaccine with a wider coverage and better protective efficacy against hypervirulent GAS strains
Reversing Antibiotic Resistance With Efflux Pump Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$494,174.00
Summary
Antibiotic resistance in dangerous pathogens is one of the greatest threats to human health of the 21st century. The main cause of multidrug resistance is the presence of drug efflux pumps, which remove antibiotics from the bacterial cell thereby lowering the antibiotic concentration inside the cells to sub-toxic levels. We will use our expertise on these efflux pumps and on how to inhibit them to develop compounds that could reverse resistance and restore the activity of antibiotics.
Targeting Nucleic Acid Synthesis And Cell Division In Gram-negative Bacterial Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$966,800.00
Summary
Some bacteria like Acinetobacter species cause infections in hospitals that are difficult to treat because they have acquired resistance to most antibiotics. This project will combine the complementary expertise of five research groups to develop knowledge of, and how to block, three essential processes in these worrying pathogenic species: copying of DNA, RNA synthesis, and cell division. This promises to lead to development of new antibacterial therapies.